Tenaya Therapeutics (TNYA)
(Delayed Data from NSDQ)
$4.40 USD
+0.12 (2.80%)
Updated May 14, 2024 04:00 PM ET
After-Market: $4.40 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
TNYA 4.40 +0.12(2.80%)
Will TNYA be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for TNYA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TNYA
Should You Buy Tenaya Therapeutics, Inc. (TNYA) After Golden Cross?
Wall Street Analysts Think Tenaya Therapeutics, Inc. (TNYA) Could Surge 273.1%: Read This Before Placing a Bet
TNYA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tenaya Therapeutics, Inc. (TNYA) Upgraded to Strong Buy: Here's Why
Wall Street Analysts Believe Tenaya Therapeutics, Inc. (TNYA) Could Rally 217.58%: Here's is How to Trade
Tenaya Therapeutics, Inc. (TNYA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for TNYA
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024
Tenaya Therapeutics reports Q1 EPS (40c), consensus (42c)
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Tenaya Therapeutics’ Strategic Advantages in Cardiovascular Genetic Medicine Garner Buy Rating